Prof. Dr. Jens Huober
Chefarzt/Chefärztin
Brustzentrum St.Gallen, Medizinische Onkologie und Hämatologie · Dept. IV, Dept. I
Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program
Schramm A, Janni W, Wallwiener D, Taran F, Hartkopf A, Meier-Stiegen F, Pantel K, Schneeweiss A, Müller V, Alunni-Fabbroni M, Trapp E, Rack B, Huober J, De Gregorio N, Scholz C, Schochter F, Friedl T, Fehm T. Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program. Arch Gynecol Obstet 2015; 293:271-81.
09.09.2015Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program
09.09.2015Arch Gynecol Obstet 2015; 293:271-81
Schramm Amelie, Janni Wolfgang, Wallwiener Diethelm, Taran Florin-Andrei, Hartkopf Andreas, Meier-Stiegen Franziska, Pantel Klaus, Schneeweiss Andreas, Müller Volkmar, Alunni-Fabbroni Marianna, Trapp Elisabeth, Rack Brigitte, Huober Jens, De Gregorio Nikolaus, Scholz Christoph, Schochter Fabienne, Friedl Thomas W P, Fehm Tanja
The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients
Bachmann H, Aminossadati B, Schmalfeldt B, Burges A, Hillemanns P, Huober J, Wollschlaeger K, Sehouli J, Siffert W, Kuhlmann J, Kimmig R, du Bois A, Meier W, Wimberger P. The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients. Br J Clin Pharmacol 2015; 80:1139-48.
22.07.2015The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients
22.07.2015Br J Clin Pharmacol 2015; 80:1139-48
Bachmann Hagen Sjard, Aminossadati Behnaz, Schmalfeldt Barbara, Burges Alexander, Hillemanns Peter, Huober Jens, Wollschlaeger Kerstin, Sehouli Jalid, Siffert Winfried, Kuhlmann Jan Dominik, Kimmig Rainer, du Bois Andreas, Meier Werner, Wimberger Pauline
Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study
Hein A, Ekici A, Hanusch C, Huober J, Liedtke C, Mau C, Moisse M, Müller V, Nekljudova V, Peuteman G, Rack B, Rübner M, Van Brussel T, Wang L, Weinshilboum R, Loibl S, Beckmann M, Kunz G, Lambrechts D, von Minckwitz G, Häberle L, Eidtmann H, Tesch H, Untch M, Hilfrich J, Schem C, Rezai M, Gerber B, Dan Costa S, Blohmer J, Schwedler K, Kittel K, Fehm T, Fasching P. Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study. Int J Cancer 2015; 137:2981-8.
06.07.2015Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study
06.07.2015Int J Cancer 2015; 137:2981-8
Hein Alexander, Ekici Arif B, Hanusch Claus, Huober Jens, Liedtke Cornelia, Mau Christine, Moisse Matthieu, Müller Volkmar, Nekljudova Valentina, Peuteman Gilian, Rack Brigitte, Rübner Matthias, Van Brussel Thomas, Wang Liewei, Weinshilboum Richard M, Loibl Sibylle, Beckmann Matthias W, Kunz Georg, Lambrechts Diether, von Minckwitz Gunter, Häberle Lothar, Eidtmann Holger, Tesch Hans, Untch Michael, Hilfrich Jörn, Schem Christian, Rezai Mahdi, Gerber Bernd, Dan Costa Serban, Blohmer Jens-Uwe, Schwedler Kathrin, Kittel Kornelia, Fehm Tanja, Fasching Peter A
A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52)
von Minckwitz G, Thomssen C, Huober J, Denkert C, Alfer J, Jackisch C, Nekljudova V, Burchardi N, Loibl S, Simon E, Stickeler E, Potenberg J, Conrad B, Reimer T, Decker T, Eidtmann H, Eiermann W, Hackmann J, Möbus V, Marme F, German Breast Group Investigators. A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52). Cancer 2015; 121:3639-48.
25.06.2015A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52)
25.06.2015Cancer 2015; 121:3639-48
von Minckwitz Gunter, Thomssen Christoph, Huober Jens, Denkert Carsten, Alfer Joachim, Jackisch Christian, Nekljudova Valentina, Burchardi Nicole, Loibl Sibylle, Simon Eike, Stickeler Elmar, Potenberg Jochem, Conrad Bettina, Reimer Toralf, Decker Thomas, Eidtmann Holger, Eiermann Wolfgang, Hackmann John, Möbus Volker, Marme Frederik, German Breast Group Investigators
Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials
Loibl S, Mehta K, Nekljudova V, Blohmer J, Costa S, Denkert C, Eidtmann H, Gerber B, Hanusch C, Hilfrich J, Huober J, Schneeweiss A, Kümmel S, Paepke S, Untch M, Lederer B, Jackisch C, von Minckwitz G. Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials. Breast Cancer Res Treat 2015; 152:377-87.
25.06.2015Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials
25.06.2015Breast Cancer Res Treat 2015; 152:377-87
Loibl Sibylle, Mehta Keyur, Nekljudova Valentina, Blohmer Jens-Uwe, Costa Serban Dan, Denkert Carsten, Eidtmann Holger, Gerber Bernd, Hanusch Claus, Hilfrich Jörn, Huober Jens, Schneeweiss Andreas, Kümmel Sherko, Paepke Stefan, Untch Michael, Lederer Bianca, Jackisch Christian, von Minckwitz Gunter
14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts
Jackisch C, Blohmer J, Costa S, Decker T, Diel I, Fasching P, Fehm T, Janni W, Lück H, Maass N, Scharl A, Beckmann M, Loibl S, Thomssen C, Harbeck N, Huober J, von Minckwitz G, Gerber B, Kreipe H, Liedtke C, Marschner N, Möbus V, Scheithauer H, Schneeweiss A, Untch M. 14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts. Breast Care (Basel) 2015; 10:211-9.
23.06.201514th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts
23.06.2015Breast Care (Basel) 2015; 10:211-9
Jackisch Christian, Blohmer Jens-Uwe, Costa Serban-Dan, Decker Thomas, Diel Ingo, Fasching Peter A, Fehm Tanja, Janni Wolfgang, Lück Hans-Joachim, Maass Nicolai, Scharl Anton, Beckmann Matthias W, Loibl Sibylle, Thomssen Christoph, Harbeck Nadia, Huober Jens, von Minckwitz Gunter, Gerber Bernd, Kreipe Hans-Heinrich, Liedtke Cornelia, Marschner Norbert, Möbus Volker, Scheithauer Heike, Schneeweiss Andreas, Untch Michael
Targeted Therapies in HER2-Positive Breast Cancer - a Systematic Review
Schramm A, De Gregorio N, Widschwendter P, Fink V, Huober J. Targeted Therapies in HER2-Positive Breast Cancer - a Systematic Review. Breast Care (Basel) 2015; 10:173-8.
18.06.2015Targeted Therapies in HER2-Positive Breast Cancer - a Systematic Review
18.06.2015Breast Care (Basel) 2015; 10:173-8
Schramm Amelie, De Gregorio Nikolaus, Widschwendter Peter, Fink Visnja, Huober Jens
Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015)
Untch M, Blohmer J, Costa S, Decker T, Diel I, Fasching P, Fehm T, Janni W, Lück H, Maass N, Scharl A, Beckmann M, Jackisch C, Thomssen C, Harbeck N, Huober J, von Minckwitz G, Gerber B, Kreipe H, Liedtke C, Marschner N, Möbus V, Scheithauer H, Schneeweiss A, Loibl S. Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015). Geburtshilfe Frauenheilkd 2015; 75:556-565.
17.06.2015Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015)
17.06.2015Geburtshilfe Frauenheilkd 2015; 75:556-565
Untch M, Blohmer J-U, Costa S-D, Decker T, Diel I, Fasching P A, Fehm T, Janni W, Lück H-J, Maass N, Scharl A, Beckmann M W, Jackisch C, Thomssen C, Harbeck N, Huober Jens, von Minckwitz G, Gerber B, Kreipe H-H, Liedtke C, Marschner N, Möbus V, Scheithauer H, Schneeweiss A, Loibl S
Chemotherapy for Metastatic Breast Cancer - An Anachronism in the Era of Personalised and Targeted Oncological Therapy?
Schneeweiss A, Ruckhäberle E, Huober J. Chemotherapy for Metastatic Breast Cancer - An Anachronism in the Era of Personalised and Targeted Oncological Therapy?. Geburtshilfe Frauenheilkd 2015; 75:574-583.
01.06.2015Chemotherapy for Metastatic Breast Cancer - An Anachronism in the Era of Personalised and Targeted Oncological Therapy?
01.06.2015Geburtshilfe Frauenheilkd 2015; 75:574-583
Schneeweiss A, Ruckhäberle E, Huober Jens
Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane-Anthracycline Containing Chemotherapy-DAFNE (GBG-70)
Hanusch C, Burchardi N, Engels K, Blohmer J, Costa S, Denkert C, Eidtmann H, Gerber B, Hilfrich J, Huober J, Jackisch C, Kümmel S, Paepke S, Untch M, Loibl S, Schneeweiss A, von Minckwitz G. Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane-Anthracycline Containing Chemotherapy-DAFNE (GBG-70). Clin Cancer Res 2015; 21:2924-31.
30.03.2015Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane-Anthracycline Containing Chemotherapy-DAFNE (GBG-70)
30.03.2015Clin Cancer Res 2015; 21:2924-31
Hanusch Claus, Burchardi Nicole, Engels Knut, Blohmer Jens Uwe, Costa Serban, Denkert Carsten, Eidtmann Holger, Gerber Bernd, Hilfrich Jörn, Huober Jens, Jackisch Christian, Kümmel Sherko, Paepke Stefan, Untch Michael, Loibl Sibylle, Schneeweiss Andreas, von Minckwitz Gunter
Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial
Erber R, Möbus V, Augustin D, Thomssen C, Jänicke F, Kiechle M, Kuhn W, Nitz U, Harbeck N, Liedtke C, Moustafa Z, Gluz O, Brünner N, Kreipe H, Pelz E, Kates R, Bartels A, Huober J, Mohrmann S, Hartmann A. Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial. Breast Cancer Res Treat 2015; 150:279-88.
28.02.2015Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial
28.02.2015Breast Cancer Res Treat 2015; 150:279-88
Erber Ramona, Möbus Volker, Augustin Doris, Thomssen Christoph, Jänicke Fritz, Kiechle Marion, Kuhn Walther, Nitz Ulrike, Harbeck Nadia, Liedtke Cornelia, Moustafa Zehra, Gluz Oleg, Brünner Nils, Kreipe Hans Heinrich, Pelz Enrico, Kates Ronald, Bartels Annette, Huober Jens, Mohrmann Svjetlana, Hartmann Arndt
Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials
Fontanella C, Schneeweiss A, Paepke S, Jackisch C, Mehta K, Nekljudova V, Untch M, Neven P, von Minckwitz G, Huober J, Hilfrich J, Hanusch C, Lederer B, Gade S, Vanoppen M, Blohmer J, Costa S, Denkert C, Eidtmann H, Gerber B, Loibl S. Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials. Breast Cancer Res Treat 2015; 150:127-39.
13.02.2015Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials
13.02.2015Breast Cancer Res Treat 2015; 150:127-39
Fontanella Caterina, Schneeweiss Andreas, Paepke Stefan, Jackisch Christian, Mehta Keyur, Nekljudova Valentina, Untch Michael, Neven Patrick, von Minckwitz Gunter, Huober Jens, Hilfrich Jörn, Hanusch Claus, Lederer Bianca, Gade Stephan, Vanoppen Mieke, Blohmer Jens Uwe, Costa Serban Dan, Denkert Carsten, Eidtmann Holger, Gerber Bernd, Loibl Sibylle
Standardized Ki67 Diagnostics Using Automated Scoring--Clinical Validation in the GeparTrio Breast Cancer Study
Klauschen F, Denkert C, Dietel M, Lederer B, Mehta K, Erbstößer E, Rüdiger T, Huober J, Blohmer J, Gerber B, Loibl S, Schmitt W, Wienert S, von Minckwitz G. Standardized Ki67 Diagnostics Using Automated Scoring--Clinical Validation in the GeparTrio Breast Cancer Study. Clin Cancer Res 2014; 21:3651-7.
11.12.2014Standardized Ki67 Diagnostics Using Automated Scoring--Clinical Validation in the GeparTrio Breast Cancer Study
11.12.2014Clin Cancer Res 2014; 21:3651-7
Klauschen Frederick, Denkert Carsten, Dietel Manfred, Lederer Bianca, Mehta Keyur, Erbstößer Erhard, Rüdiger Thomas, Huober Jens, Blohmer Jens-Uwe, Gerber Bernd, Loibl Sibylle, Schmitt Wolfgang D, Wienert Stephan, von Minckwitz Gunter
Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA
Krop I, Welslau M, Samant M, Miles D, Lu M, Huober J, Guardino E, Blackwell K, Lin N, Diéras V. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. Ann Oncol 2014; 26:113-119.
29.10.2014Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA
29.10.2014Ann Oncol 2014; 26:113-119
Krop I E, Welslau M, Samant M, Miles D, Lu M, Huober Jens, Guardino E, Blackwell K, Lin N U, Diéras V
Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy
Lindner J, Tesch H, Karn T, Pommerenke F, Liedtke C, Untch M, Müller V, Rack B, Schem C, Engels K, Huober J, Sinn B, Loibl S, Denkert C, Ataseven B, Fasching P, Pfitzner B, Gerber B, Gade S, Darb-Esfahani S, von Minckwitz G. Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy. Ann Oncol 2014; 26:95-100.
29.10.2014Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy
29.10.2014Ann Oncol 2014; 26:95-100
Lindner J L, Tesch H, Karn T, Pommerenke F, Liedtke C, Untch M, Müller V, Rack B, Schem C, Engels K, Huober Jens, Sinn B V, Loibl S, Denkert C, Ataseven B, Fasching P A, Pfitzner B M, Gerber B, Gade S, Darb-Esfahani S, von Minckwitz G
The ratio of the estradiol metabolites 2-hydroxyestrone (2-OHE1) and 16α-hydroxyestrone (16-OHE1) may predict breast cancer risk in postmenopausal but not in premenopausal women: two case-control studies
Ruan X, Seeger H, Wallwiener D, Huober J, Mueck A. The ratio of the estradiol metabolites 2-hydroxyestrone (2-OHE1) and 16α-hydroxyestrone (16-OHE1) may predict breast cancer risk in postmenopausal but not in premenopausal women: two case-control studies. Arch Gynecol Obstet 2014; 291:1141-6.
16.10.2014The ratio of the estradiol metabolites 2-hydroxyestrone (2-OHE1) and 16α-hydroxyestrone (16-OHE1) may predict breast cancer risk in postmenopausal but not in premenopausal women: two case-control studies
16.10.2014Arch Gynecol Obstet 2014; 291:1141-6
Ruan Xiangyan, Seeger Harald, Wallwiener Diethelm, Huober Jens, Mueck Alfred O
Bone targeted therapy in breast cancer - an old concept but still much to do
Huober J, Thürlimann B. Bone targeted therapy in breast cancer - an old concept but still much to do. Breast Care (Basel) 2014; 9:310.
01.10.2014Bone targeted therapy in breast cancer - an old concept but still much to do
01.10.2014Breast Care (Basel) 2014; 9:310
Huober Jens, Thürlimann Beat
Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studies
Salmen J, Sohn C, Fehm T, Mohrmann S, Loehberg C, Hein A, Schulz-Wendtland R, Hartkopf A, Brucker S, Wallwiener D, Friese K, Hartmann A, Beckmann M, Janni W, Rom J, Heil J, Neugebauer J, Fasching P, Haeberle L, Huober J, Wöckel A, Rauh C, Schuetz F, Weissenbacher T, Kost B, Stickeler E, Klar M, Orlowska-Volk M, Windfuhr-Blum M, Rack B. Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studies. Breast Cancer Res Treat 2014; 148:143-51.
25.09.2014Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studies
25.09.2014Breast Cancer Res Treat 2014; 148:143-51
Salmen Jessica, Sohn Christof, Fehm Tanja, Mohrmann Svjetlana, Loehberg Christian R, Hein Alexander, Schulz-Wendtland Ruediger, Hartkopf Andreas D, Brucker Sara Y, Wallwiener Diethelm, Friese Klaus, Hartmann Arndt, Beckmann Matthias W, Janni Wolfgang, Rom Joachim, Heil Joerg, Neugebauer Julia, Fasching Peter A, Haeberle Lothar, Huober Jens, Wöckel Achim, Rauh Claudia, Schuetz Florian, Weissenbacher Tobias, Kost Bernd, Stickeler Elmar, Klar Maximilian, Orlowska-Volk Marzenna, Windfuhr-Blum Marisa, Rack Brigitte
PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer
Loibl S, Fasching P, Andre F, Lindner J, Sotiriou C, Dykgers A, Guo S, Gade S, Nekljudova V, Loi S, Untch M, Pfitzner B, Huober J, Heinrichs C, von Minckwitz G, Schneeweiss A, Paepke S, Lehmann A, Rezai M, Zahm D, Sinn P, Khandan F, Eidtmann H, Dohnal K, Denkert C. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer. J Clin Oncol 2014; 32:3212-20.
08.09.2014PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer
08.09.2014J Clin Oncol 2014; 32:3212-20
Loibl Sibylle, Fasching Peter A, Andre Fabrice, Lindner Judith L, Sotiriou Christos, Dykgers August, Guo Sanxing, Gade Stephan, Nekljudova Valentina, Loi Sherene, Untch Michael, Pfitzner Berit, Huober Jens, Heinrichs Clemens, von Minckwitz Gunter, Schneeweiss Andreas, Paepke Stefan, Lehmann Annika, Rezai Mahdi, Zahm Dirk M, Sinn Peter, Khandan Fariba, Eidtmann Holger, Dohnal Karel, Denkert Carsten
Distinct expression of cytokeratin, N-cadherin and CD133 in circulating tumor cells of metastatic breast cancer patients
Bock C, Rack B, Huober J, Andergassen U, Jeschke U, Doisneau-Sixou S. Distinct expression of cytokeratin, N-cadherin and CD133 in circulating tumor cells of metastatic breast cancer patients. Future Oncol 2014; 10:1751-65.
01.08.2014Distinct expression of cytokeratin, N-cadherin and CD133 in circulating tumor cells of metastatic breast cancer patients
01.08.2014Future Oncol 2014; 10:1751-65
Bock Carolin, Rack Brigitte, Huober Jens, Andergassen Ulrich, Jeschke Udo, Doisneau-Sixou Sophie